2-(2,4-dichlorophenyl)aniline | 212138-75-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,4-dichlorophenyl)aniline
• 英文别名: 2-amino-(2',4'-dichloro)biphenyl；2-amino-6,8-dichlorobiphenyl；[1,1'-Biphenyl]-2-amine, 2',4'-dichloro-
• CAS: 212138-75-5
• 化学式: C₁₂H₉Cl₂N
• 分子量: 238.116
• InChiKey: JHEBVXZGMJNMPR-UHFFFAOYSA-N

物化性质

• 沸点：
  345.8±27.0 °C(Predicted)
• 密度：
  1.316±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2,4-dichlorophenyl)aniline 在 对甲苯磺酸 作用下， 以 二苯醚 、 苯 为溶剂， 反应 0.58h， 生成 8-(2,4-dichlorophenyl)-2-methyl-4-hydroxyquinoline
  参考文献：
  名称：

  Synthesis and SAR of 8-Arylquinolines as potent corticotropin-Releasing factor1 (CRF1) receptor antagonists

  摘要：

  A series of 4-substituted 8-aryl-2-methylquinolines 4 was designed and synthesized as highly potent antagonists for the human CRF1 receptor. This series of compounds displayed parallel SAR to other bicyclic systems such as pyrazolo[l,5-a]pyrimidines, with several compounds possessing low nanomolar binding affinity. In addition to the high potency, the basicity of this 4-aminoquinoline core may offer CRF1 antagonists with lower lipophilicity. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00684-x
• 作为产物：
  描述：

  2,4-二氯苯硼酸 、 2-溴苯胺 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 以72%的产率得到2-(2,4-dichlorophenyl)aniline
  参考文献：
  名称：

  CRF receptor antagonists and methods relating thereto

  摘要：

  揭示了CRF受体拮抗剂，其在治疗各种疾病方面具有用途，包括治疗温血动物中CRF过度分泌表现的疾病，例如中风。

  公开号：

  US06352990B1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：Sheth Urvi

  公开号：US20120309758A1

  公开（公告）日：2012-12-06

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及调节ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白，以及相关的组合物和方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。
• Palladium-catalyzed stereospecific C–P coupling toward diverse PN-heterocycles
  作者：Hong Deng、Minyan Wang、Yong Liang、Xiangyang Chen、Tianhang Wang、Jonathan J. Wong、Yue Zhao、Kendall N. Houk、Zhuangzhi Shi

  DOI：10.1016/j.chempr.2022.01.005

  日期：2022.2

  sulfur-based heterocyclic compounds. However, the study of such molecules remains difficult because of a lack of synthetic methods with which to synthesize them, especially with respect to the construction of P-stereogenic centers. Here, we present a simple, versatile method for the synthesis of PN-heterocycles bearing P(V) centers from phosphanamines through palladium-catalyzed intramolecular C–P coupling

  含磷杂环引起了特别的兴趣，因为它们表现出与常见的氧、氮和/或硫基杂环化合物明显不同的性质。然而，由于缺乏合成它们的合成方法，尤其是在构建 P-立体中心方面，对此类分子的研究仍然很困难。在这里，我们提出了一种简单、通用的方法，用于通过钯催化的分子内 C-P 偶联从磷胺合成带有 P(V) 中心的 PN-杂环。在开发的催化体系下，手性 PN-杂环可以由 P(III)-立体前体生产而不会失去立体化学的完整性。计算研究揭示了详细的反应途径和立体特异性的起源。
• CRF antagonistic quino- and quinazolines
  申请人：——

  公开号：US06482836B1

  公开（公告）日：2002-11-19

  This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is C1-6alkyl, NR6R7, OR6 or SR7; R2 is hydrogen, C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is Ar1 or Het1; R4 and R5 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, cyano, nitro, amino, and mono- or di(C1-6alkyl)amino; R6 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R7 is hydrogen, C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxy-C1-6alkyl or C1-6alkyloxyC1-6alkyl; R6 is C1-8alkyl, mono- or di(C3-6cycloalkyl)-methyl, Ar2CH2, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl; or R6 and R7 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C1-6alkyl or C1-6alkyloxyC1-6alkyl; and Ar1 and Ar2 are each optionally substituted phenyl; and Het1 is optionally substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).

  本发明涉及公式化合物，包括其立体异构体和药学上可接受的酸加成盐形式，其中R1是C1-6烷基、NR6R7、OR6或SR7；R2是氢、C1-6烷基、C1-6烷氧基或C1-6烷基硫基；R3是Ar1或Het1；R4和R5各自独立地选自氢、卤素、C1-6烷基、C1-6烷氧基、三氟甲基、氰基、硝基、氨基和单或双(C1-6烷基)氨基；R6是氢、C1-6烷基、C1-6烷基磺酰基、C1-6烷基磺酸氧基或C1-6烷基硫基；R7是氢、C1-8烷基、单或双(C3-6环烷基)甲基、C3-6环烷基、C3-6烯基、羟基C1-6烷基、C1-6烷基羧酸酯-C1-6烷基或C1-6烷氧基C1-6烷基；R6是C1-8烷基、单或双(C3-6环烷基)-甲基、Ar2CH2、C1-6烷氧基C1-6烷基、羟基C1-6烷基、C3-6烯基、噻吩基甲基、呋喃基甲基、C1-6烷基硫基C1-6烷基、单或双(C1-6烷基)氨基C1-6烷基、双(C1-6烷基)氨基、C1-6烷基羧酰基C1-6烷基；或R6和R7与它们连接的氮原子一起可以形成吡咯烷基、哌嗪基、同型哌嗪基或吗啉基，可选择地取代C1-6烷基或C1-6烷氧基C1-6烷基；Ar1和Ar2各自可选地取代苯基；Het1是可选地取代的吡啶基；具有CRF受体拮抗性质的制剂；将此类化合物作为活性成分的制药组合物；通过给予公式(I)化合物的有效量来治疗与CRF过度分泌相关的疾病，如抑郁症、焦虑症、物质滥用等。